{"schema_version":"secwatch.filing_event.v1","accession":"0001851734-23-000037","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.826498+00:00","generated_at":"2026-06-19T22:45:18.113978+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vistagen completes Pherin acquisition, reports Q3 net loss $9.8M; PH94B Phase 3 adjusted","bullets":["Acquired Pherin Pharmaceuticals; eliminated all future royalty obligations on PH94B and PH10; added three new pherine candidates.","PH94B Phase 3 plan: PALISADE-1 had unexpected results; preparing FDA meeting; considering multiple-administration LSAS study.","PH10 received FDA Fast Track designation for major depressive disorder; Phase 1 trial underway; Phase 2A AjDA topline results expected Q1 2023.","Q3 net loss $9.8M vs $10.7M YoY; R&D decreased $0.9M to $6.9M; cash $25.0M at Dec 31, 2022.","Shares outstanding 219.3M, including ~12.4M shares issued for Pherin acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001851734-23-000037","json":"https://secwatch.observer/filing/0001851734-23-000037.json","markdown":"https://secwatch.observer/filing/0001851734-23-000037.md","text":"https://secwatch.observer/filing/0001851734-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/0001851734-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/vtgn20230207_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:45:18.113978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8b74a1bab6bc6101acb93686ebe8b7181486dc4","claim":"Vistagen Therapeutics, Inc. reported financial results for fiscal year 2023 third quarter ended December 31, 2022.","evidence_excerpt":"On February 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 third quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/0001851734-23-000037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023 third quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}